February 9, 2026 — Leads & Copy — Estrella Immunopharma, Inc. presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings.
The presentation highlighted clinical data from the ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL).
In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated a 100% Complete Response (CR) rate in the high-dose cohort at Month 1. All patients who achieved a CR have remained in CR through the data cutoff.
The median Duration of Complete Response (DOCR) has not yet been reached, with response durations currently ranging from 3 to 18 months. Clinical highlights also include a complete responder with Primary Central Nervous System Lymphoma (PCNSL), a highly aggressive NHL subtype.
Most patients enrolled in this study are considered high-risk and were ineligible for existing commercial CD19 products. To date, the STARLIGHT-1 study (n=9) has reported no treatment-related serious adverse events (SAEs).
According to Dr. Naseem Esteghamat, Principal Investigator of the STARLIGHT-1 study at University of California, Davis, the clinical findings give confidence as they continue to advance this potentially transformative therapy.
Cheng Liu, PhD, Chief Executive Officer of Estrella, said that the data represent an important milestone for Estrella and underscore the potential of EB103 to address the unmet medical need in B-cell NHL. The unique design of ARTEMIS T cells aims to address the safety barriers and durability limitations of conventional CD19 CAR-T therapies.
Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS technology to target CD19. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS technology to target not only CD19, but also CD22.
A copy of the abstract presented at the 2026 Tandem Meetings is available at https://tandem.virtual-meeting.org/programme/abstract/299719.
For more information about Estrella, please visit www.estrellabio.com.
Source: Estrella Immunopharma, Inc.
